A process for the preparation of 2-substituted-1,4-benzenediamines, a cosmetically acceptable salt thereof, or mixture thereof. The process according to the present invention is a particularly cost effective process in that it avoids sophisticated chemical steps which requires special equipment or expensive catalysts and in that it comprises a recycling step of one of the starting materials, namely the 2-substituted aniline.

Compositions and methods are provided for reducing, inhibiting, or preventing corrosion of a surface, the method comprising contacting an anticorrosion compound of Formula 1 with the surface, the anticorrosion compound of Formula 1 having a structure corresponding to:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently selected from hydrogen, hydroxyl, alkyl, alkoxyl, aryl, alkaryl, aralkyl, and —NR.sup.8R.sup.9; R.sup.6 and R.sup.7 are independently hydrogen, a substituted alkyl, substituted alkenyl, substituted aryl, substituted alkaryl, or substituted aralkyl, wherein at least one substituent is a hydroxyl or an ether; provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen; Fe and R.sup.9 are independently hydrogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted aryl, unsubstituted alkaryl, unsubstituted aralkyl, substituted alkyl, substituted alkenyl, or substituted alkaryl, wherein at least one substituent is a hydroxyl or an ether; or any two adjacent groups of R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 form one or more ring structures.

Compositions and methods are provided for reducing, inhibiting, or preventing corrosion of a surface, the method comprising contacting an anticorrosion compound of Formula 1 with the surface, the anticorrosion compound of Formula 1 having a structure corresponding to:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are independently selected from hydrogen, hydroxyl, alkyl, alkoxyl, aryl, alkaryl, aralkyl, and —NR.sup.8R.sup.9; R.sup.6 and R.sup.7 are independently hydrogen, a substituted alkyl, substituted alkenyl, substituted aryl, substituted alkaryl, or substituted aralkyl, wherein at least one substituent is a hydroxyl or an ether; provided that at least one of R.sup.6 and R.sup.7 is other than hydrogen; Fe and R.sup.9 are independently hydrogen, unsubstituted alkyl, unsubstituted alkenyl, unsubstituted aryl, unsubstituted alkaryl, unsubstituted aralkyl, substituted alkyl, substituted alkenyl, or substituted alkaryl, wherein at least one substituent is a hydroxyl or an ether; or any two adjacent groups of R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 form one or more ring structures.

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.

The present invention relates to a polyethylene glycol derivative and a preparation method thereof. A preparation process of a polyethylene glycol derivative, according to the present invention, may provide a novel polyethylene glycol derivative which can be utilized in various ways as a drug linker, and is appropriate and effective for mass production and is advantageous in reproducible mass production of high-quality products.

The present invention relates to a polyethylene glycol derivative and a preparation method thereof. A preparation process of a polyethylene glycol derivative, according to the present invention, may provide a novel polyethylene glycol derivative which can be utilized in various ways as a drug linker, and is appropriate and effective for mass production and is advantageous in reproducible mass production of high-quality products.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I):

##STR00001##

or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q.sub.1, Q.sub.2, Z, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

The invention relates to processes for preparing 2-methoxymethyl-p-phenylenediamine (I), cosmetically acceptable salts thereof, or mixtures thereof.

The invention relates to processes for preparing 2-methoxymethyl-p-phenylenediamine (I), cosmetically acceptable salts thereof, or mixtures thereof.